I earned my PhD at the University of Bergen on organoid models and novel biomarkers for improved treatment of endometrial cancer. I am currently a postdoctoral fellow in the Bergen Gynecological Research Group, where my main focus is to study drug resistance and identify new treatment strategies for endometrial cancer patients. Currently, I am working on a study that applies advanced functional genomics to identify genes responsible for carboplatin resistance. This new knowledge will be used to find novel treatments for chemotherapy resistant endometrial cancers.

Vitenskapelig artikkel

• Mari Kyllesø Halle; Erlend Hodneland; Kari Strøno Wagner-Larsen et al. (2024). Radiomic profiles improve prognostication and reveal targets for therapy in cervical cancer. (ekstern lenke)
• Hege Fredriksen Berg; Zhenlin Ju; Madeleine Myrvold et al. (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. (ekstern lenke)
• David Erik Forsse; Hege Fredriksen Berg; Olivera Bozickovic et al. (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. (ekstern lenke)
• Heidi Espedal; Kristine Eldevik Fasmer; Hege Fredriksen Berg et al. (2024). MRI radiomics captures early treatment response in patient-derived organoid endometrial cancer mouse models. (ekstern lenke)
• Marike S. Lombaers; Casper Reijnen; Ally Sprik et al. (2025). ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment. (ekstern lenke)
• Hege Fredriksen Berg; Hilde Renate Engerud; Madeleine Myrvold et al. (2022). Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. (ekstern lenke)
• Madeleine Charlotte van der Berg; Hege Fredriksen Berg; Tomasz Stokowy et al. (2024). Expression patterns of mismatch repair proteins in cervical cancer uncover independent prognostic value of MSH-2. (ekstern lenke)
• Hilde Eide Lien; Hege Fredriksen Berg; Mari Kyllesø Halle et al. (2023). Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease. (ekstern lenke)
• Hilde Renate Engerud; Hege Fredriksen Berg; Madeleine Myrvold et al. (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. (ekstern lenke)
• Erling Andre Høivik; Erlend Hodneland; Julie Andrea Dybvik et al. (2021). A radiogenomics application for prognostic profiling of endometrial cancer. (ekstern lenke)
• Hilde Renate Engerud; Kirsten Øvergaard Hope; Hege Fredriksen Berg et al. (2019). Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. (ekstern lenke)
• Hege Fredriksen Berg; Marta Espevold Hjelmeland; Hilde Eide Lien et al. (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. (ekstern lenke)
• Hilde Eide Lien; Marta Espevold Hjelmeland; Hege Fredriksen Berg et al. (2025). Multiplex single-cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer. (ekstern lenke)
• Marit Louise Ulvang; Oda Vik Fløtre; Hege Fredriksen Berg et al. (2025). Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions. (ekstern lenke)
• Marta Espevold Hjelmeland; Hilde Eide Lien; Hege Fredriksen Berg et al. (2024). Loss of vimentin expression in preoperative biopsies independently predicts poor prognosis, lymph node metastasis and recurrence in endometrial cancer. (ekstern lenke)
• Tina Fonnes; Hege Fredriksen Berg; Therese Bredholt Onyango et al. (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. (ekstern lenke)
• Camilla Krakstad; Hege Fredriksen Berg; Kristina Yvonne Kathe Lindemann et al. (2024). Frequency of ERBB2-Low Expression in Endometrial Cancer. (ekstern lenke)
• Tina Fonnes; Elin Strand; Kristine Eldevik Fasmer et al. (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. (ekstern lenke)
• Heidi Espedal; Hege Fredriksen Berg; Tina Fonnes et al. (2021). Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. (ekstern lenke)
• Heidi Espedal; Jenny Margrethe Lyngstad; Hege Fredriksen Berg et al. (2025). Evaluation of early chemotherapy response by combining static- and dynamic [¹⁸F]FDG-PET with diffusion-weighted MRI in subcutaneous patient-derived endometrial cancer mouse models. (ekstern lenke)
• Ingvild Løberg Tangen; Kristine Eldevik Fasmer; Gonda F Konings et al. (2018). Blood steroids are associated with prognosis and fat distribution in endometrial cancer. (ekstern lenke)
• Mari Kyllesø Halle; Ingvild Løberg Tangen; Hege Fredriksen Berg et al. (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. (ekstern lenke)
• Hege Fredriksen Berg; Jone Trovik; Marta Espevold Hjelmeland et al. (2025). Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining. (ekstern lenke)

Rettelse i tidsskrift

• Hege Fredriksen Berg; Marta Espevold Hjelmeland; Hilde Eide Lien et al. (2021). Author Correction: Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis (Communications Medicine, (2021), 1, 1, (20), 10.1038/s43856-021-00019-x). (ekstern lenke)
• Hilde Eide Lien; Hege Fredriksen Berg; Mari Kyllesø Halle et al. (2023). Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595] (eBioMedicine (2023) 92, (S2352396423001603), (10.1016/j.ebiom.2023.104595)). (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin